



Summary of updates to East Region Formulary (ERF) website.

The purpose of this summary is to detail the main changes to the ERF. The website chapters should be referred to for full details. All of the amendments detailed appear on the new website platform which can be found here: formulary.nhs.scot/east/.

Note that there are a few remaining paediatric chapters on the new website platform for the East Region Formulary that are old Lothian recommendations awaiting review by representatives from the region.

TIPS: See the 'History Notes' for a brief description of the change and the date of the change, as in the example below.

A Treatment of pain in palliative care ^

Prescribing Notes:

- The [National Palliative Care Guidelines](#) have been developed by a multidisciplinary group of professionals working in the community, hospital and specialist palliative care services throughout Scotland and are used in all Scottish Health Boards.
- The guidelines reflect a consensus of opinion about good practice in the management of adult patients with a life limiting illness.
- Guidelines on individual symptoms are available. Each page has some introductory information, links to related guidelines and web resources. The individual guidelines are in PDF format and can be downloaded or printed off.

History Notes ^

20/10/2020	Content migrated from LJF website.
------------	------------------------------------

Chapter	Adult or Child	Group	Condition	New content	Month of ERWG/ ERFC
Anaesthesia	Child	Various pathways		Review of ERF recommendations in reference to MHRA DSU opioids post operative pain.	July 2025
Anaesthesia	Adult	Peri-operative treatment	Central and respiratory depression	Dantrolene 120mg powder for solution for injection vials added as original strength discontinued.	July 2025
CNS	Adult	Substance dependence	Alcohol dependence	Pabrinex IM discontinued, and IV Pabrinex affected by long-term supply issues. Licensed Thiamine 250mg/5ml solution for injection ampoules included as alternative.	May 2025
CNS	Adult	Multiple sclerosis	Multiple sclerosis	Addition of Ublituximab: Briumvi (SMC2731). New formulation of Ocrelizumab included with use in line with former approvals for highly active RRMS and early primary progressive MS.	May 2025
CNS	Adult	Depression	Depression & Anxiety Disorders (pathway 3, 4 and remove 5)	Updates to pathway titles. Voriooxetine and Esketamine moved from pathways to Formulary Decisions only.	July 2025
CNS	Adult	CNS	Epilepsy	Carbamazepine 100mg/5ml oral solution removed and replaced with Carbamazepine 100mg/5ml oral suspension sugar free.	July 2025
CNS	Adult	CNS	Trigeminal Neuralgia	Carbamazepine 100mg/5ml oral solution removed and replaced with Carbamazepine 100mg/5ml oral suspension sugar free.	July 2025
CNS	Child	Various pathways		Review of ERF recommendations in reference to MHRA DSU opioids post operative pain.	July 2025
CNS	Adult and Child	Pain & Osteoarthritis	Pain > 'Pain with a neuropathic component OR neuropathic pain' and Osteoarthritis 'Treatment of Osteoarthritis with a topical preparation'	Lidocaine plasters and topical Capsaicin - review and updates to prescribing information in view of national guidance on medicines of low and limited clinical value and current availability of licensed topical capsaicin products.	July 2025
CNS	Adult	Depression & Anxiety Disorders	Depression & OCD	Revised dosing guidance for Fluoxetine.	August 2025

Chapter	Adult or Child	Group	Condition	New content	Month of ERWG/ ERFC
Ear, nose, and oropharynx	Adult	Ear, nose, and oropharynx	Oropharynx and oral cavity	Bioxtra discontinued. Oralieve moisturising mouth gel added as new alternative first choice.	May 2025
Endocrine	Adult	Sex hormones	Menopausal symptoms	Premarin 0.625mg and 1.25mg tablets debranded to conjugated oestrogens 625microgram tablets and 1.25mg tablets, respectively.	July 2025
Endocrine	Adult and Child	Diabetes Mellitus	Diabetes Mellitus - type 1 and Diabetes Mellitus - type 2	MSAN (2025)29 Insulatard penfill 100units/ml suspension for injection 3ml cartridges, MSAN (2025)30 Levemir Flexpen 100units/ml solution for injection pre-filled pens and Levemir Penfill 100units/ml solution for injection 3ml cartridges.	July 2025
Endocrine	Adult	Bone metabolism	Osteoporosis	Teriparatide (Teva) added.	July 2025
Endocrine	Adult and Child	Diabetes Mellitus	Diabetes Mellitus - type 1 and Diabetes Mellitus - type 2	MSAN (2025)37 - Humulin I (insulin isophane human) 100units/ml suspension for injection 10ml vials; Humulin M3 (insulin isophane biphasic human 30/70) 100units/ml suspension for injection 10ml vials; Humalog mix25 (insulin lispro biphasic 25/75) 100units/ml suspension for injection 10ml vials; Humulin S (insulin soluble human) 100units/ml solution for injection 10ml vials.	August 2025
Endocrine	Adult and Child	Diabetes Mellitus	Diabetes Mellitus - type 1 and Diabetes Mellitus – type 2	MSAN (2025)41 Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and Levemir® (insulin detemir) Penfill 100units/ml solution being discontinued.	August 2025
Endocrine	Adult and Child	Diabetes Mellitus	Diabetes Mellitus - type 1 and Diabetes Mellitus - type 2	MSAN(2025)41 Levemir (insulin detemir) FlexPen 100units/ml solution for injection 3ml pre-filled pens and Levemir (insulin detemir) Penfill 100units/ml solution discontinued.	August 2025

Chapter	Adult or Child	Group	Condition	New content	Month of ERWG/ ERFC
Eye	Child	Eye conditions	Uveitis > 'Systemic treatment of uveitis' and other eye conditions covered as part of MSK chapter review	New Pathway content agreed.	May 2025
Infections	Adult and Child	Ear, Nose & Oropharynx	Otitis Externa	Otomize ear spray debranded.	July 2025
Musculoskeletal and joint diseases	Adult	Musculoskeletal and joint diseases	Familial Mediterranean Fever	Addition of Colchicine 500microgram tablets (UI).	May 2025
Musculoskeletal and joint diseases	Child	Musculoskeletal and joint diseases	Musculoskeletal and joint diseases	Whole chapter review.	May 2025
Musculoskeletal and joint diseases	Adult	Musculoskeletal and joint diseases	Raynaud's Phenomenon	New Pathway content agreed.	May 2025
Musculoskeletal and joint diseases	Adult	Musculoskeletal and joint diseases	Rheumatoid Arthritis > 'Treatment of Rheumatoid Arthritis with local corticosteroids'	Triamcinolone hexacetonide 20mg/ml suspension for injection ampules and triamcinolone acetoneide (kenalog intra-articular/intramuscular 40mg/ml suspension for injection vials) discontinued	July 2025
Nutrition & Blood	Adult	Obesity	Obesity	New obesity pathway – Liraglutide: Saxenda, Semaglutide: Wegovy, Tirzepatide: Mounjaro, and Orlistat.	May 2025
Nutrition & Blood	Child	Obesity	Obesity	New obesity pathway – Liraglutide: Saxenda and Semaglutide: Wegovy.	August 2025

Chapter	Adult or Child	Group	Condition	New content	Month of ERWG/ ERFC
Obstetrics, gynaecology, and urinary-tract disorders	Adult	Gynaecology	Contraception	Addition of Levonorgestrel Jaydess 13.5mg intrauterine device.	May 2025
Obstetrics, gynaecology, and urinary-tract disorders	Adult	Obstetrics	Lactation	Update to Domperidone prescribing information and addition of links to further guidance.	May 2025
Obstetrics, gynaecology, and urinary-tract disorders	Adult	Gynaecology	Uterine Fibroids	Addition of Linzagolix: Yselty (SMC2631).	August 2025
Obstetrics, gynaecology, and urinary-tract disorders	Adult	Gynaecology	Endometriosis	Addition of Relugolix, estradiol, norethisterone acetate: Ryeqo (SMC2666).	August 2025
Respiratory	Child	Respiratory	Asthma	Addition of Fobumix Easyhaler and SIGN updates.	May 2025
Respiratory	Adult	Respiratory	Asthma	Relevant SIGN/BTS updates. Luforbec removed from formulary choices and replaced by Proxor 100/6 micrograms inhaler.	May 2025
Respiratory	Adult and Child	Respiratory	Asthma	Whole chapter review reflecting recent updates to SIGN guidelines.	May 2025
Respiratory	Adult and Child	Respiratory	Respiratory disorders > Allergy	Removal of chlorphenamine oral solution SF from adult pathways as majority will be able to use tablets. Addition of chlorphenamine oral solution in addition to SF option in child pathways.	July 2025
Skin	Adult and Child	Skin Conditions	Pruritus	Removal of chlorphenamine oral solution SF from adult pathways as majority will be able to use tablets. Addition of chlorphenamine oral solution in addition to SF option in child pathways.	July 2025

Chapter	Adult or Child	Group	Condition	New content	Month of ERWG/ ERFC
Skin	Adult and Child	Skin conditions	Warts	Salicylic Acid Occlusal 26% w/w solution removed as discontinued from June 2025.	August 2025
Skin	Adult	Skin conditions	Actinic keratosis and Superficial basal cell carcinoma	Efudix (Fluorouracil) 5% cream debranded to Fluorouracil 5% cream.	August 2025
Wound care	Adult	Antimicrobial wound management products	Antimicrobial dressings - honey based	Medihoney dressings discontinued.	August 2025

To review Formulary Decisions noted at the East Region Formulary Committee refer to the [Minutes of East Region Formulary Committee](#) or alternatively search [Formulary Decisions](#) with the relevant start date. See example below:

Lothian Joint Formulary

[Therapeutic Areas](#) [Medicines A-Z](#) [Conditions A-Z](#) [Medicine Categories](#) [Formulary Decisions](#)

[Home](#) > [Formulary Decisions](#)

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Generic medicine name

Medicine brand name

Therapeutic area

Start date

End date

Source

Lothian

Help

Update

[Privacy and cookies](#)

[Terms and conditions](#)

[Contact us](#)

© Copyright

Healthier Scotland
Scottish Government

NHS
SCOTLAND